AP partners with WEF for energy centre in Amaravati
A Government Order issued on Thursday formalized the establishment of this centre, which will operate under the WEF's global Centre for the Fourth Industrial Revolution (C4IR) Network. Notably, it will be India's first thematic C4IR centre and will focus on two critical areas: energy transition and green industries in collaboration with WEF's Centre for Energy and Materials (CENMAT) and AI-led digital transformation and cyber security, in partnership with WEF's Centre for Cyber Security.
This initiative stems from high-level meetings with the WEF in Davos and is poised to position Amaravati as India's leading center for green energy, sustainability, and cyber security.
The project is being spearheaded by Chief Minister N Chandrababu Naidu and IT Minister Nara Lokesh, with the overarching goal of enhancing AP's international profile and attracting significant investments in clean energy, Artificial Intelligence, and digital infrastructure.
The centre's key objectives include elevating AP's global standing, fostering international partnerships, supporting the growth of green industries, enhancing cyber security capabilities, and running pilot projects in clean energy, smart grids, and the application of AI in sectors such as agriculture and governance. Furthermore, it aims at upskilling the workforce in cyber security and emerging technologies and connecting the state with prominent global platforms like the WEF's annual meeting at Davos.
The state government has allocated Rs 36 crore to support the Centre's operations for three years. It will initially function from Vijayawada or Amaravati and will be governed by a high-level committee chaired by IT Minister Nara Lokesh.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
9 minutes ago
- Indian Express
Jharkhand liquor scam: After arrest of businessman, Opp demands cancellation of ambulance tender process
The Opposition parties in Maharashtra have demanded the cancellation of a multi-thousand crore ambulance tender process after the arrest of Amit Salunkhe — one of the contractors in the project — by Jharkhand police in the Jharkhand liquor scam. 'The director of Sumeet Facilities has been arrested by Jharkhand police. We have been alleging for over a year that he is a part of over Rs 6,000-crore ambulance scam in the state. We raised the issue multiple times but the government neglected it. We will surely bring out more evidence, but as of now, it is important that the tender is stayed,' said NCP-SP MLA Rohit Pawar. Shiv Sena (UBT) leader Sanjay Raut on Friday accused the Maharashtra government of committing an 'ambulance scam' of Rs 800 crore, and claimed the money involved was diverted to a foundation run by Shiv Sena MP Shrikant Shinde, a charge rejected by the ruling party. Raut said a tender was floated by the state government for procurement of ambulances and its contract was awarded to a firm run by a close aide of Shrikant Shinde, son of Maharashtra Deputy Chief Minister Eknath Shinde. 'The probe will bring out how much money has gone to a certain foundation for the election. It is clear that the present Maharashtra government needs clean up,' said Raut. Earlier this week, Salunkhe was arrested by Jharkhand police in an alleged Jharkhand liquor scam. Salunkhe is an 11th arrest in this case and he is said to be close to Chhattisgarh businessman Siddharth Singhania, who is already under arrest. In Maharashtra, Sumeet Facilities was given a tender to run ambulances (108 helpline) for the next 10 years along with BVG group. The tender was issued in the previous state government led by Chief Minister Eknath Shinde and the Public Health minister was Tanaji Sawant. The Opposition had then alleged that the tender was issued at triple rates and extended undue benefits to the contractors. However, state Industries Minister and Shiv Sena leader Uday Samant rejected the allegations levelled by Raut. 'The charges have no basis. Shrikant Shinde has proved his worth as a part of the (Operation Sindoor) delegation (to countries which was led by several MPs including Shrikant Shinde). Maharashtra's people will not attach any value to such allegations,' the minister said.
&w=3840&q=100)
Business Standard
11 minutes ago
- Business Standard
Schaeffler India Q1FY26 results: Net profit increases 14% to ₹294 crore
The company had posted a standalone PAT of Rs 253.96 crore in the year-ago quarter, according to a regulatory filing Press Trust of India Mumbai Auto parts maker Schaeffler India on Friday reported a 14 per cent rise in standalone profit after tax (PAT) to Rs 294.44 crore in the June 2025 quarter. The company had posted a standalone PAT of Rs 253.96 crore in the year-ago quarter, according to a regulatory filing. Schaeffler India follows a January-December financial year. Its revenue from operations (net) for the quarter under review rose to Rs 2,282.16 crore from Rs 2,071.93 crore in the April-June period of 2024, it stated. "We have a year-on-year higher revenue across all businesses and continue to sustain our trajectory of registering double-digit growth for the fifth consecutive quarter. Quality of earnings continued to improve given efficiency measures and concentrated efforts on our strategic priority of localisation," its Managing Director and Chief Executive Officer Harsha Kadam said. This performance, coupled with improved financial and operating metrics, resulted in a good first half of 2025, he added.
&w=3840&q=100)
Business Standard
11 minutes ago
- Business Standard
Cipla Q1 net profit up 10%, driven by consumer health and generics
Pharma major Cipla posted a 10 per cent year-on-year increase in its consolidated net profit, reaching Rs 1,297 crore in the first quarter of financial year 2026 (Q1FY26), up from Rs 1,177 crore. Revenue from operations also rose by 3.2 per cent YoY, reaching Rs 6,837 crore compared to Rs 6,672 crore last year. The increase in profit and revenue was attributed to robust performance in the consumer healthcare and generic markets. Sequentially, revenue was up by 3.6 per cent, with net profit increasing by 6.2 per cent. The results were announced during market hours. Cipla's stock rose by 2.95 per cent, ending the day's trade at Rs 1,531.10 on the BSE. Umang Vohra, Managing Director and Global Chief Executive Officer of Cipla, stated, 'I am pleased to share that we continue to make considerable progress across our focused markets. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipelines, and focusing on resolving regulatory challenges.' For FY26, Cipla has guided for EBITDA margins between 23.5 per cent and 24.5 per cent. Growth will be driven by respiratory product launches in the US, new rollouts in India and emerging markets, and strong momentum in the GLP-1 segment, which is seen as a transformative opportunity. While US revenue forecasts remain conservative due to expected Lenalidomide erosion, the company is confident that its expanding pipeline will offset the impact. This quarter, Cipla's India business reported strong performance across all segments. In branded prescription, key therapies like respiratory, urology, cardiac, anti-diabetes, and anti-infectives outpaced market growth, with the chronic portfolio forming 61.5 per cent of sales. Trade generics saw robust growth, aided by strong execution, new product introductions (including entry into orthopaedics), and tech-led initiatives, with seven product launches during the quarter. In consumer health, anchor brands Nicotex, Omnigel, and Cipladine retained leadership in their categories. In North America, Cipla posted revenue of $226 million, driven by differentiated assets. Albuterol reached 19.5 per cent market share, while Lanreotide reached 21 per cent. Launches like nano paclitaxel vials and Nilotinib capsules are set to boost Cipla's oncology and complex generics presence. A strategic tie-up will also bring its first U.S. biosimilar to market in Q2 FY26. For Africa, the company delivered an 11 per cent YoY growth in USD terms, with private market growth. Cipla ranked number 3 overall in South Africa's private market, with its prescription business at number 2, driven by growth in key therapies, tender business, and new launches. In the emerging markets and Europe, the company's focused strategy yielded 8 per cent growth in USD terms, supported by momentum in both DTM and B2B segments, while maintaining stable margins. Cipla also reported a relatively higher research and development (R&D) spend this quarter at 6.2 per cent of revenue. The company sees its biggest growth opportunity in executing a strong pipeline of new product launches, particularly in the respiratory segment, with 3–4 launches lined up for the US and several more planned for emerging markets and India. Cipla is also continuing to actively invest in biosimilars and mRNA platforms, with a Centre of Excellence in Europe, capacity building at its Goa facility, and collaboration with Ethris. A biosimilar in supportive therapy is on track for launch in FY26. The company is also advancing early-stage work in CAR-T and cell/gene therapies, with ongoing evaluations and potential partnerships. Cipla holds a strong net cash position of Rs 10,800 crore and maintains a cautious, science-led M&A strategy, prioritising differentiated, patient-centric products over plain-vanilla brand acquisitions. Internal capital expenditure and R&D investments remain elevated to support long-term growth. From a risk perspective, potential US tariffs are not expected to materially impact generics, though branded products may face greater pressure. Regulatory scrutiny remains a key risk, particularly in manufacturing compliance. Cipla eyes Day 1 launch of GLP-1 drug in 2026 Cipla has identified the GLP-1 category—led by blockbuster drug Semaglutide—as its most significant therapeutic opportunity in the next five years. The company aims for a Day 1 launch after patents expire in mid-2026, using a mix of in-house and partner filings in key global markets. Calling the GLP-1 space 'transformational,' Cipla is adopting a dual filing strategy through both in-house development and external partnerships to ensure early market entry. 'We see the GLP-1 category, including Semaglutide, as one of the biggest therapy opportunities in the last five years,' said Umang Vohra, Managing Director and Global CEO of Cipla. 'Our approach is a mix of own and partner filings to ensure market presence from day one, especially in key markets.' In India, Cipla is working on an economically viable strategy not only for Semaglutide but for the entire GLP-1 portfolio, anticipating price erosion post-2026 but offset by volume growth. Cipla is also monitoring a recent Delhi High Court order restricting fixed-dose GLP-1 combinations but does not anticipate major disruptions for mono-variant GLP-1 therapies. Earlier, Dr. Reddy's Laboratories revealed plans to enter the GLP-1 space with Semaglutide across 87 countries starting in 2026.
